ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results
SEOUL, South Korea, March 11, 2024 /PRNewswire/ — ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical… อ่านเพิ่ม